Large patient population is suffering from moderate to severe psoriatic arthritis with unmet medical needs, and the number is increasing across the globe. This disease falls in the progressive category of diseases that may get worse over time. If left untreated, psoriatic arthritis may lead to joint damage permanently due to the degeneration of the cartilages present in the joints. Treatment of psoriatic arthritis involves the use of biologic drugs, enzyme inhibitors, disease-modifying rheumatoid arthritis drugs, and nonsteroidal anti-inflammatory drugs. Several drugs are into clinical testing which depicts the possibility of discovering new molecules with maximum activity and minimum side effects.
The market is driven by an increase in the prevalence of psoriatic arthritis, new product development, rise in adoption of biologics for the treatment of moderate to severe psoriatic arthritis and large patient population with unmet medical needs across the globe. The high cost of the drugs, generic erosion and treatment and lack of standardization tools for diagnosis and treatment are going to restrain the market in the forecast period.
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
